TITLE

Study supports anti-VEGF, laser for patients with diabetic macular edema

AUTHOR(S)
Boyle, Erin L.; Harcharek, Alexandra; Hasson, Matt; Hsvidas, Cara; Nale, Patricia; Master, Joseph; Pagnani, Michelle; Preston, Courtney
PUB. DATE
February 2011
SOURCE
Ocular Surgery News;2/25/2011, Vol. 29 Issue 4, p24
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports that intravitreal ranibizumab with deferred or prompt focal/grid laser has resulted to superior to optical coherence tomography outcome and superior visual acuity than in focal/grid laser treatment alone in visually impaired patients according to doctor Neil M. Bressler.
ACCESSION #
86439052

 

Related Articles

  • Comparison studies of anti-VEGF agents a 'global effort'. Boyle, Erin L.; Harcharek, Alexandra; Hasson, Matt; Hsvidas, Cara; Nale, Patricia; Master, Joseph; Pagnani, Michelle; Preston, Courtney // Ocular Surgery News;2/25/2011, Vol. 29 Issue 4, p25 

    The article reports on the presentation by doctor Daniel F. Martin on the comparison studies and international effort to understand the differences between the two anti-vascular endothelial growth factor (VEGF) agents, ranibizumab and bevacizumab.

  • Exploring anti-VEGF therapy for wet AMD: What dosing strategy is best? Boyle, Erin L.; Harcharek, Alexandra; Hasson, Matt; Hsvidas, Cara; Nale, Patricia; Master, Joseph; Pagnani, Michelle; Preston, Courtney // Ocular Surgery News;2/25/2011, Vol. 29 Issue 4, p22 

    The article offers insights from doctor Philip J. Rosenfeld regarding the best dosing strategy for studying anti-vascular endothelial growth factors (VEGF) therapy for wet age-related macular degeneration (AMD).

  • Anti-VEGF patterns of use may vary for DME cases in clinical practice. Harrison, Laird // Ophthalmology Times;Sep2015, Vol. 40 Issue 15, p70 

    The article presents the results of a study on the effectiveness of anti-vascular endothelial growth factor (VEGF) treatments for diabetic macular edema conducted by Dr. Kevin Blinder at Washington University in St. Louis, Missouri. Topics mentioned include disappointing results in clinical...

  • Anti-VEGF maintains visual acuity gains at 1 year in patients with neovascular AMD. Hasson, Matt; Pagnani, Michelle; Preston, Courtney // Ocular Surgery News;3/25/2011, Vol. 29 Issue 6, p31 

    The article reports on the study which found that pegatinib, an induction-maintenance therapy, can improve visual acuity and stabilized center point thickness in patients that have neovascular age-related macular degeneration.

  • Anti-VEGF best option for managing macular edema caused by CRVO. Boyle, Erin L.; Harcharek, Alexandra; Hasson, Matt; Hsvidas, Cara; Nale, Patricia; Master, Joseph; Pagnani, Michelle; Preston, Courtney // Ocular Surgery News;2/25/2011, Vol. 29 Issue 4, p25 

    The article offers the insights of doctor Neil M. Bressler regarding the efficacy of monthly intravitreal injection of ranibizumab in treating macular edema caused by central retinal vein occlusion (CRVO).

  • Anti-angiogenic agent continues to show promise for treating DME.  // Ocular Surgery News;3/10/2011, Vol. 29 Issue 5, p17 

    The article presents research showing the improvements brought by anti-angiogenic agent for the treatment of patients with diabetic macular edema.

  • Special considerations needed for pseudophakic patients with DME. Boyle, Erin L.; Harcharek, Alexandra; Hasson, Matt; Hsvidas, Cara; Nale, Patricia; Master, Joseph; Pagnani, Michelle; Preston, Courtney // Ocular Surgery News;2/25/2011, Vol. 29 Issue 4, p24 

    The article offers the insights of doctor Susan B. Bressler regarding the need for special approach to pseudophakic patients with diabetic macular edema (DME) during the Hawaiian Eye 2011.

  • A Clinical Perspective... Kitchens, John // Ophthalmology Times;Apr2015 Supplement, p2 

    The author discusses how the Protocol T study results gave him more insight for treating patients both with adequate and poorer baseline visual acuity and reassured him of the effectiveness of anti-vascular endothelial growth factor (VEGFs).

  • Evidence favors anti-VEGFs for DME. Meszaros, Liz; Wenick, Adam S. // Ophthalmology Times;3/15/2013, Vol. 38 Issue 6, p12 

    The article discusses research which examines the use of anti-vascular endothelial growth factor (VEGF) agents for the management of patients with diabetic macular edema (DME) and other eye disorders. Findings from randomized clinical trials showed the efficacy of ranibizumab to reduce the risk...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics